PCSK9 and familial hypercholesterolemia: Hence, apart from its favorable and proven efficacy, PCSK9i provides more flexibility to be used in the context of severe hypercholesterolemia, regardless of genotype status (monogenic vs. polygenic vs. unidentified mutation or LDLR vs. APOB vs. PCSK9 mutation).